Compare BIO-TECHNE Corp (TECH) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Wells Fargo & Co — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while Wells Fargo & Co trades at $82 (market cap $242.71B). The key difference: Wells Fargo & Co is far larger — about 21.3× BIO-TECHNE Corp's market cap, and Wells Fargo & Co pays the higher dividend (2.49%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Wells Fargo & Co for 87 Days on average.
| TECH | WFC | |
|---|---|---|
Market Cap | $11.37B | $242.71B |
Volume | 3,153,511 | 13,542,533 |
Sector | Health | Financials |
52-Week High | $72.61 | $96.40 |
52-Week Low | $43.31 | $73.42 |
Typical Hold Time | 63 Days | 87 Days |
Enterprise Value | $11.40B | $498.47B |
Dividend Yield | 0.44% | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Wells Fargo (WFC) trades at $82.06, up 0.67% today, with a bearish technical signal despite recent earnings beat. The stock shows strong fundamentals with 25.97% net income margin and 13.13% ROE, trading at attractive valuations (P/E 11.67, P/B 1.47). Recent credit rating upgrade to 'A-' by S&P and stable Fed stress test changes provide positive catalysts, though negative operating cash flow of -$19B in 2025 raises concerns.
WFC presents a compelling value opportunity with analyst consensus target of $99.13 (21% upside), supported by improving profitability and stable regulatory environment. Key risks include volatile cash flows, rising interest rate pressures, and execution challenges in maintaining recent momentum. The balanced analyst sentiment (47% Buy, 47% Hold) suggests cautious optimism for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
